RXRX

Recursion Pharmaceuticals Inc.distress 4/10 · elevated risk

$2.980%today-56% from 52w high

recursion.com600 employeesFounded 2013Salt Lake City, UTBiotechnology

Infectious Disease 1Oncology 1

Lead: Solid Tumor · target MEK

Revenue

pre-revenue

Liquidity

$654M

Runway

2.0 yrs

Shares 1y

—

Price & events

-39.9% over 6M

CatalystRating changeDilutionFinancingdashed = today

-0.0%

-1.3%

-5.7%

-14.9%

-37.0%

-53.7%

-65.3%

-91.5%

-90.5%

All

Overview

Market Cap: $501.58M
Volume: 1.34M
52 Week Range: $2.84 – $6.79
Total Shares: 168.32M
Float Shares: 513.01M
Short %: 34.41%
% Held by Insiders: 2.37%
% Held by Institutions: 68.85%
RVOL: 0.06x
Beta: 0.99

Pipeline stages · 4 programs

REC-1245

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2027-06

GTAEXS617, SoC

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2028-01

EXS73565

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2028-06

EXS74539

Preclin›

Ph1›

Ph2›

Ph3›

Filed›

PDUFA›

Approved

next 2029-03

Pipeline · 9 trials · 5 upcoming

Readout	Phase	Drug	Indication	Enroll	Status
2027-06 Estimated 50% readout ~2027-07-16	Phase 1/2	REC-4881	Familial Adenomatous Polyposis	—	recruiting
2028-01 Estimated 50% readout ~2028-02-15	Phase 1/2	GTAEXS617, SoC	Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC), Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma, Triple Negative Breast Cancer (TNBC)	—	recruiting
2028-06 Estimated 50% readout ~2028-07-01	Phase 1	EXS73565	Relapsed or Refractory B-cell Malignancies, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL), Mantle Cell Lymphoma (MCL), Diffuse-large B-cell Lymphoma (DLBCL), Waldenstrom's Macroglobulinemia (WM)	—	recruiting
2028-10-30 Estimated 50% readout ~2028-12-14	Phase 1/2	REC-1245	Unresectable, Locally Advanced, Metastatic Cancers, Relapsed/Refractory Lymphomas	—	recruiting
2029-03 Estimated 50% readout ~2029-03-31	Phase 1	EXS74539	Solid Tumor, Small Cell Lung Cancer (SCLC), High Grade Neuroendocrine Cancer, Small Cell Carcinomas of Non-lung Origin, Non-small Cell Lung Cancer (NSCLC), Prostate Cancer, Ovarian Cancer, Renal Carcinoma (Clear and Non-clear Cell), Head and Neck Squamous Cell Carcinoma (HNSCC), Hepatic Cancer, Gastric Cancer, Triple-negative Breast Cancer (TNBC)	—	recruiting

Show all 9 trials · 4 more ▾

Readout	Phase	Drug	Indication	Enroll	Status
2025-08-18	Phase 2/3	REC-2282	Neurofibromatosis Type 2	25	terminated
2025-06-30	Phase 2	REC-994	Cerebral Cavernous Malformation	62	completed
2025-05-06	Phase 2	REC-3964	Recurrent Clostridioides Difficile Infection	3	terminated
2025-02-24	Phase 2	REC-4881	AXIN1 Gene Mutation, APC Gene Mutation, Solid Tumor	18	terminated